| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Asthma | 29 | 2020 | 1077 | 2.920 |
Why?
|
| Polymorphism, Single Nucleotide | 37 | 2024 | 2555 | 1.550 |
Why?
|
| Genome-Wide Association Study | 28 | 2024 | 1849 | 1.500 |
Why?
|
| Genetic Predisposition to Disease | 20 | 2019 | 2552 | 1.170 |
Why?
|
| Bronchopulmonary Dysplasia | 4 | 2025 | 48 | 1.040 |
Why?
|
| Intrauterine Devices | 1 | 2026 | 34 | 0.920 |
Why?
|
| Nerve Block | 1 | 2026 | 55 | 0.910 |
Why?
|
| Genetic Association Studies | 2 | 2017 | 310 | 0.860 |
Why?
|
| Shock | 1 | 2023 | 55 | 0.750 |
Why?
|
| Respiratory Insufficiency | 2 | 2023 | 210 | 0.750 |
Why?
|
| Genetic Loci | 11 | 2019 | 263 | 0.730 |
Why?
|
| Evolution, Molecular | 7 | 2012 | 902 | 0.710 |
Why?
|
| Spermatozoa | 3 | 2006 | 69 | 0.600 |
Why?
|
| Indians, North American | 3 | 2017 | 49 | 0.560 |
Why?
|
| Genome, Human | 8 | 2016 | 832 | 0.540 |
Why?
|
| Alleles | 10 | 2020 | 1159 | 0.530 |
Why?
|
| Genetic Variation | 8 | 2017 | 1445 | 0.510 |
Why?
|
| Gene Frequency | 10 | 2017 | 715 | 0.470 |
Why?
|
| Bronchiolitis, Viral | 1 | 2015 | 6 | 0.460 |
Why?
|
| Receptors, Adrenergic, beta-2 | 1 | 2015 | 39 | 0.460 |
Why?
|
| Infant, Premature | 4 | 2023 | 306 | 0.460 |
Why?
|
| Genotype | 15 | 2020 | 1888 | 0.430 |
Why?
|
| Humans | 74 | 2026 | 97913 | 0.420 |
Why?
|
| Infant, Extremely Premature | 2 | 2025 | 45 | 0.420 |
Why?
|
| X Chromosome | 2 | 2006 | 154 | 0.410 |
Why?
|
| Genetics, Population | 6 | 2020 | 449 | 0.380 |
Why?
|
| Proteins | 4 | 2014 | 804 | 0.380 |
Why?
|
| Psychodidae | 3 | 2003 | 7 | 0.380 |
Why?
|
| Chromosomes, Human, Pair 6 | 2 | 2014 | 127 | 0.370 |
Why?
|
| Electronic Health Records | 1 | 2017 | 439 | 0.360 |
Why?
|
| Selection, Genetic | 5 | 2013 | 571 | 0.350 |
Why?
|
| Immunoglobulin E | 3 | 2020 | 156 | 0.340 |
Why?
|
| Female | 41 | 2026 | 51441 | 0.340 |
Why?
|
| Mexican Americans | 4 | 2020 | 72 | 0.340 |
Why?
|
| Male | 41 | 2025 | 46983 | 0.330 |
Why?
|
| Infant, Newborn | 6 | 2025 | 2525 | 0.330 |
Why?
|
| Child | 17 | 2022 | 7687 | 0.310 |
Why?
|
| Pulmonary Surfactants | 2 | 2021 | 22 | 0.300 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 4 | 2014 | 443 | 0.290 |
Why?
|
| Cross-Sectional Studies | 2 | 2026 | 2033 | 0.280 |
Why?
|
| Tandem Mass Spectrometry | 3 | 2025 | 108 | 0.280 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2009 | 164 | 0.280 |
Why?
|
| Chromosome Mapping | 8 | 2018 | 1061 | 0.280 |
Why?
|
| Polymorphism, Genetic | 2 | 2009 | 831 | 0.270 |
Why?
|
| Adaptation, Physiological | 2 | 2012 | 346 | 0.260 |
Why?
|
| Biological Evolution | 2 | 2006 | 1067 | 0.260 |
Why?
|
| Lung | 3 | 2019 | 1403 | 0.250 |
Why?
|
| Albuterol | 2 | 2018 | 36 | 0.240 |
Why?
|
| Bronchodilator Agents | 2 | 2018 | 72 | 0.230 |
Why?
|
| Models, Genetic | 4 | 2018 | 1004 | 0.230 |
Why?
|
| Chromosomes, Human, X | 1 | 2006 | 56 | 0.230 |
Why?
|
| Adolescent | 16 | 2018 | 10078 | 0.220 |
Why?
|
| Fertility | 1 | 2005 | 120 | 0.220 |
Why?
|
| Infant | 3 | 2023 | 3325 | 0.210 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2025 | 53 | 0.210 |
Why?
|
| Cost-Benefit Analysis | 2 | 1997 | 522 | 0.210 |
Why?
|
| Acetaminophen | 1 | 2025 | 63 | 0.210 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2004 | 112 | 0.210 |
Why?
|
| Case-Control Studies | 6 | 2019 | 1995 | 0.210 |
Why?
|
| Testis | 1 | 2004 | 150 | 0.210 |
Why?
|
| Lung Transplantation | 2 | 2019 | 386 | 0.200 |
Why?
|
| Gene Duplication | 1 | 2004 | 129 | 0.200 |
Why?
|
| Hydrocortisone | 2 | 2023 | 306 | 0.200 |
Why?
|
| Haplotypes | 6 | 2020 | 656 | 0.200 |
Why?
|
| Retinopathy of Prematurity | 1 | 2025 | 81 | 0.190 |
Why?
|
| Disease | 2 | 2017 | 92 | 0.190 |
Why?
|
| Sex Characteristics | 1 | 2005 | 350 | 0.190 |
Why?
|
| Environmental Exposure | 2 | 2017 | 404 | 0.190 |
Why?
|
| Chromosomes, Human, Pair 17 | 3 | 2019 | 110 | 0.190 |
Why?
|
| Metabolome | 1 | 2023 | 70 | 0.180 |
Why?
|
| Premature Birth | 1 | 2024 | 131 | 0.180 |
Why?
|
| Mutagenesis | 1 | 2002 | 195 | 0.180 |
Why?
|
| Genomics | 3 | 2024 | 896 | 0.170 |
Why?
|
| Insect Vectors | 2 | 2003 | 11 | 0.170 |
Why?
|
| Enzymes | 1 | 2001 | 47 | 0.170 |
Why?
|
| Adult | 15 | 2026 | 29498 | 0.170 |
Why?
|
| Budesonide | 1 | 2021 | 46 | 0.160 |
Why?
|
| Risk | 4 | 2018 | 660 | 0.160 |
Why?
|
| Odds Ratio | 3 | 2017 | 726 | 0.160 |
Why?
|
| Metabolomics | 1 | 2021 | 106 | 0.160 |
Why?
|
| Nitric Oxide | 2 | 2018 | 286 | 0.160 |
Why?
|
| Drosophila | 1 | 2004 | 547 | 0.160 |
Why?
|
| HLA-DRB1 Chains | 1 | 2020 | 24 | 0.160 |
Why?
|
| Leishmaniasis, Visceral | 1 | 1999 | 4 | 0.150 |
Why?
|
| Telomere-Binding Proteins | 1 | 2019 | 14 | 0.150 |
Why?
|
| Parents | 1 | 2022 | 321 | 0.150 |
Why?
|
| Lectins, C-Type | 1 | 2019 | 74 | 0.150 |
Why?
|
| United States | 11 | 2020 | 8155 | 0.150 |
Why?
|
| Primary Graft Dysfunction | 1 | 2019 | 49 | 0.150 |
Why?
|
| Alveolitis, Extrinsic Allergic | 1 | 2019 | 45 | 0.150 |
Why?
|
| Receptors, Corticotropin-Releasing Hormone | 1 | 2018 | 5 | 0.140 |
Why?
|
| Risk Factors | 7 | 2018 | 6220 | 0.140 |
Why?
|
| Proteome | 1 | 2020 | 163 | 0.140 |
Why?
|
| Chromosomes, Human, Pair 18 | 1 | 2018 | 43 | 0.140 |
Why?
|
| Allografts | 1 | 2019 | 218 | 0.140 |
Why?
|
| Smad2 Protein | 1 | 2018 | 25 | 0.140 |
Why?
|
| HLA Antigens | 1 | 2020 | 238 | 0.140 |
Why?
|
| Telomere | 1 | 2019 | 130 | 0.140 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2018 | 41 | 0.140 |
Why?
|
| Chromosomes | 1 | 2018 | 91 | 0.140 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2021 | 358 | 0.140 |
Why?
|
| Gene Flow | 2 | 2016 | 107 | 0.140 |
Why?
|
| Administration, Inhalation | 1 | 2018 | 206 | 0.130 |
Why?
|
| Multifactorial Inheritance | 1 | 2020 | 234 | 0.130 |
Why?
|
| Pharmacogenomic Variants | 1 | 2018 | 46 | 0.130 |
Why?
|
| Lupus Nephritis | 1 | 2018 | 85 | 0.130 |
Why?
|
| Confidence Intervals | 1 | 1997 | 220 | 0.130 |
Why?
|
| Puerto Rico | 5 | 2016 | 34 | 0.130 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2017 | 113 | 0.130 |
Why?
|
| GATA3 Transcription Factor | 2 | 2014 | 53 | 0.130 |
Why?
|
| Tacrolimus | 1 | 2018 | 376 | 0.130 |
Why?
|
| Ikaros Transcription Factor | 2 | 2014 | 26 | 0.130 |
Why?
|
| Models, Statistical | 2 | 2017 | 601 | 0.120 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2018 | 303 | 0.120 |
Why?
|
| Child, Preschool | 5 | 2015 | 4000 | 0.120 |
Why?
|
| Health Services Research | 1 | 1997 | 144 | 0.120 |
Why?
|
| Animals | 11 | 2016 | 28864 | 0.120 |
Why?
|
| Human Migration | 1 | 2016 | 31 | 0.120 |
Why?
|
| Gene-Environment Interaction | 1 | 2017 | 125 | 0.120 |
Why?
|
| Linkage Disequilibrium | 3 | 2012 | 482 | 0.120 |
Why?
|
| Host-Parasite Interactions | 1 | 2016 | 35 | 0.120 |
Why?
|
| CD56 Antigen | 1 | 2015 | 18 | 0.120 |
Why?
|
| Software | 2 | 2017 | 694 | 0.120 |
Why?
|
| Respiratory Syncytial Viruses | 1 | 2015 | 13 | 0.120 |
Why?
|
| Up-Regulation | 1 | 2018 | 743 | 0.120 |
Why?
|
| S100 Proteins | 1 | 2015 | 51 | 0.110 |
Why?
|
| Genetics, Medical | 1 | 2015 | 51 | 0.110 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2017 | 298 | 0.110 |
Why?
|
| Genomic Imprinting | 1 | 2015 | 32 | 0.110 |
Why?
|
| Myosin-Light-Chain Kinase | 1 | 2015 | 41 | 0.110 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2016 | 159 | 0.110 |
Why?
|
| Exome | 1 | 2015 | 145 | 0.110 |
Why?
|
| Young Adult | 8 | 2014 | 7490 | 0.110 |
Why?
|
| Minority Groups | 1 | 2016 | 156 | 0.110 |
Why?
|
| Respiration, Artificial | 1 | 2018 | 456 | 0.110 |
Why?
|
| Sequence Analysis, DNA | 3 | 2017 | 911 | 0.110 |
Why?
|
| Calcium-Binding Proteins | 1 | 2015 | 122 | 0.110 |
Why?
|
| DNA Methylation | 2 | 2017 | 730 | 0.110 |
Why?
|
| DNA-Binding Proteins | 4 | 2014 | 1255 | 0.110 |
Why?
|
| Adaptive Immunity | 1 | 2016 | 193 | 0.110 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2014 | 82 | 0.110 |
Why?
|
| Air Pollution | 1 | 2016 | 118 | 0.110 |
Why?
|
| Cholecalciferol | 1 | 1994 | 37 | 0.100 |
Why?
|
| Interpersonal Relations | 1 | 2015 | 182 | 0.100 |
Why?
|
| Founder Effect | 1 | 2014 | 106 | 0.100 |
Why?
|
| Interleukin-4 | 2 | 2016 | 136 | 0.100 |
Why?
|
| Rhinitis, Allergic | 1 | 2014 | 53 | 0.100 |
Why?
|
| Hip Fractures | 1 | 1994 | 54 | 0.100 |
Why?
|
| Gestational Age | 2 | 2025 | 341 | 0.100 |
Why?
|
| Neoplasm Proteins | 2 | 2014 | 550 | 0.100 |
Why?
|
| Mice | 6 | 2016 | 12682 | 0.100 |
Why?
|
| Immunosuppressive Agents | 1 | 2018 | 1012 | 0.100 |
Why?
|
| Kv Channel-Interacting Proteins | 1 | 2013 | 9 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 10 | 1 | 2013 | 47 | 0.100 |
Why?
|
| Retrospective Studies | 2 | 2026 | 10922 | 0.100 |
Why?
|
| Likelihood Functions | 2 | 2004 | 258 | 0.100 |
Why?
|
| Prevalence | 1 | 2017 | 1381 | 0.100 |
Why?
|
| HLA-DQ beta-Chains | 1 | 2012 | 13 | 0.100 |
Why?
|
| Venezuela | 3 | 2003 | 9 | 0.090 |
Why?
|
| Socioeconomic Factors | 1 | 2015 | 661 | 0.090 |
Why?
|
| Fatty Acid Desaturases | 1 | 2012 | 17 | 0.090 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2014 | 280 | 0.090 |
Why?
|
| Kallikreins | 1 | 2012 | 47 | 0.090 |
Why?
|
| Cohort Studies | 5 | 2019 | 3207 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 2012 | 61 | 0.090 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 1997 | 1002 | 0.090 |
Why?
|
| RNA | 2 | 2019 | 593 | 0.090 |
Why?
|
| Untranslated Regions | 1 | 2012 | 18 | 0.090 |
Why?
|
| Sulfonamides | 1 | 2014 | 351 | 0.090 |
Why?
|
| Immunity, Innate | 1 | 2016 | 481 | 0.090 |
Why?
|
| Pyrimidines | 1 | 2014 | 411 | 0.090 |
Why?
|
| Graft Rejection | 1 | 2018 | 1186 | 0.090 |
Why?
|
| Multigene Family | 1 | 2012 | 204 | 0.090 |
Why?
|
| Mutation | 2 | 2019 | 4389 | 0.090 |
Why?
|
| Open Reading Frames | 1 | 2012 | 118 | 0.090 |
Why?
|
| Caribbean Region | 1 | 2011 | 28 | 0.090 |
Why?
|
| Gene Regulatory Networks | 1 | 2014 | 336 | 0.090 |
Why?
|
| Stearoyl-CoA Desaturase | 1 | 2011 | 4 | 0.090 |
Why?
|
| Fatty Acids, Omega-6 | 1 | 2011 | 9 | 0.090 |
Why?
|
| Logistic Models | 3 | 2025 | 1274 | 0.090 |
Why?
|
| Computational Biology | 1 | 2015 | 611 | 0.080 |
Why?
|
| North America | 1 | 2011 | 209 | 0.080 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 2 | 2001 | 238 | 0.080 |
Why?
|
| Exons | 1 | 2012 | 450 | 0.080 |
Why?
|
| Transcription Factors | 3 | 2014 | 1711 | 0.080 |
Why?
|
| Prostate-Specific Antigen | 1 | 2012 | 353 | 0.080 |
Why?
|
| United Kingdom | 3 | 2007 | 208 | 0.080 |
Why?
|
| Autoimmune Diseases | 1 | 2012 | 258 | 0.080 |
Why?
|
| Multivariate Analysis | 2 | 2025 | 1008 | 0.070 |
Why?
|
| Introns | 3 | 2018 | 300 | 0.070 |
Why?
|
| Phenotype | 4 | 2018 | 2638 | 0.070 |
Why?
|
| Recombination, Genetic | 1 | 2011 | 423 | 0.070 |
Why?
|
| Mexico | 3 | 2015 | 75 | 0.070 |
Why?
|
| Organ Specificity | 2 | 2015 | 287 | 0.070 |
Why?
|
| Pan troglodytes | 1 | 2009 | 203 | 0.070 |
Why?
|
| Algorithms | 2 | 2015 | 2008 | 0.070 |
Why?
|
| Gene Expression Regulation | 3 | 2015 | 2022 | 0.060 |
Why?
|
| Mental Health Services | 1 | 2007 | 95 | 0.060 |
Why?
|
| Middle Aged | 8 | 2020 | 29366 | 0.060 |
Why?
|
| Genes, Essential | 1 | 2005 | 19 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2021 | 1946 | 0.060 |
Why?
|
| Gene Expression Profiling | 1 | 2011 | 1566 | 0.060 |
Why?
|
| Gene Expression | 1 | 2009 | 1320 | 0.060 |
Why?
|
| Ductus Arteriosus, Patent | 1 | 2025 | 45 | 0.050 |
Why?
|
| Codon | 1 | 2004 | 116 | 0.050 |
Why?
|
| Data Interpretation, Statistical | 2 | 2015 | 312 | 0.050 |
Why?
|
| Patient Care Team | 1 | 2007 | 318 | 0.050 |
Why?
|
| Base Sequence | 3 | 2016 | 2222 | 0.050 |
Why?
|
| Demography | 3 | 2009 | 193 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 14 | 2 | 2014 | 50 | 0.050 |
Why?
|
| Leishmaniasis, Cutaneous | 1 | 2003 | 8 | 0.050 |
Why?
|
| Primary Health Care | 1 | 2007 | 395 | 0.050 |
Why?
|
| Molecular Sequence Data | 2 | 2004 | 2896 | 0.050 |
Why?
|
| Reproducibility of Results | 3 | 2015 | 2785 | 0.050 |
Why?
|
| Aged | 5 | 2020 | 21703 | 0.050 |
Why?
|
| Mental Disorders | 1 | 2007 | 483 | 0.050 |
Why?
|
| Epigenesis, Genetic | 2 | 2017 | 588 | 0.050 |
Why?
|
| Amino Acid Substitution | 1 | 2002 | 334 | 0.040 |
Why?
|
| Electrophoresis, Cellulose Acetate | 1 | 2001 | 3 | 0.040 |
Why?
|
| Sex Factors | 2 | 2015 | 1138 | 0.040 |
Why?
|
| Reproduction | 1 | 2002 | 212 | 0.040 |
Why?
|
| Limit of Detection | 1 | 2021 | 22 | 0.040 |
Why?
|
| Dried Blood Spot Testing | 1 | 2021 | 9 | 0.040 |
Why?
|
| Chromatography, Liquid | 1 | 2021 | 102 | 0.040 |
Why?
|
| Exoribonucleases | 1 | 2019 | 9 | 0.040 |
Why?
|
| Histocompatibility Testing | 1 | 2020 | 145 | 0.040 |
Why?
|
| Computer Simulation | 2 | 2015 | 1152 | 0.040 |
Why?
|
| Rats | 1 | 2006 | 4071 | 0.040 |
Why?
|
| Telomerase | 1 | 2019 | 69 | 0.040 |
Why?
|
| Muscle Contraction | 1 | 2020 | 267 | 0.040 |
Why?
|
| Muscle, Smooth | 1 | 2020 | 299 | 0.040 |
Why?
|
| Bronchi | 1 | 2020 | 228 | 0.040 |
Why?
|
| DNA Helicases | 1 | 2019 | 91 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 2019 | 64 | 0.040 |
Why?
|
| Isoenzymes | 1 | 1999 | 272 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2019 | 83 | 0.040 |
Why?
|
| Exercise Therapy | 1 | 1999 | 96 | 0.040 |
Why?
|
| Low Back Pain | 1 | 1999 | 62 | 0.040 |
Why?
|
| Surface-Active Agents | 1 | 2018 | 58 | 0.040 |
Why?
|
| Proteomics | 1 | 2020 | 278 | 0.030 |
Why?
|
| Histone Code | 1 | 2017 | 19 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2021 | 973 | 0.030 |
Why?
|
| Genetic Markers | 1 | 2018 | 471 | 0.030 |
Why?
|
| Planning Techniques | 1 | 1997 | 10 | 0.030 |
Why?
|
| Budgets | 1 | 1997 | 10 | 0.030 |
Why?
|
| State Medicine | 1 | 1997 | 15 | 0.030 |
Why?
|
| Cell Cycle Proteins | 1 | 2019 | 419 | 0.030 |
Why?
|
| Rhinitis, Allergic, Seasonal | 1 | 2017 | 179 | 0.030 |
Why?
|
| Efficiency, Organizational | 1 | 1997 | 55 | 0.030 |
Why?
|
| Dexamethasone | 1 | 2018 | 318 | 0.030 |
Why?
|
| DNA, Intergenic | 1 | 2016 | 28 | 0.030 |
Why?
|
| Leukocytes | 1 | 2017 | 212 | 0.030 |
Why?
|
| Pregnancy | 1 | 2024 | 3243 | 0.030 |
Why?
|
| Transplant Recipients | 1 | 2018 | 182 | 0.030 |
Why?
|
| Genetic Heterogeneity | 1 | 2016 | 71 | 0.030 |
Why?
|
| Protein S | 1 | 2016 | 1 | 0.030 |
Why?
|
| Nippostrongylus | 1 | 2016 | 4 | 0.030 |
Why?
|
| Strongylida Infections | 1 | 2016 | 7 | 0.030 |
Why?
|
| Pyroglyphidae | 1 | 2016 | 15 | 0.030 |
Why?
|
| Research Support as Topic | 1 | 1997 | 97 | 0.030 |
Why?
|
| Glucocorticoids | 1 | 2018 | 369 | 0.030 |
Why?
|
| Gene Knockout Techniques | 1 | 2016 | 84 | 0.030 |
Why?
|
| Sexism | 1 | 2016 | 64 | 0.030 |
Why?
|
| Geography | 1 | 2016 | 249 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2017 | 422 | 0.030 |
Why?
|
| Blood Proteins | 1 | 2016 | 147 | 0.030 |
Why?
|
| Spain | 1 | 2015 | 36 | 0.030 |
Why?
|
| Phylogeny | 2 | 2016 | 1337 | 0.030 |
Why?
|
| HLA-DQ alpha-Chains | 1 | 2014 | 16 | 0.030 |
Why?
|
| Databases, Nucleic Acid | 1 | 2015 | 45 | 0.030 |
Why?
|
| Nuclear Proteins | 1 | 2019 | 749 | 0.030 |
Why?
|
| Pharmacogenetics | 1 | 2018 | 472 | 0.030 |
Why?
|
| Nedd4 Ubiquitin Protein Ligases | 1 | 2014 | 14 | 0.030 |
Why?
|
| Philadelphia Chromosome | 1 | 2014 | 48 | 0.030 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2014 | 40 | 0.030 |
Why?
|
| Endosomal Sorting Complexes Required for Transport | 1 | 2014 | 17 | 0.030 |
Why?
|
| Air Pollutants | 1 | 2016 | 116 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 1 | 2017 | 976 | 0.030 |
Why?
|
| Population Groups | 1 | 2014 | 44 | 0.030 |
Why?
|
| Indazoles | 1 | 2014 | 63 | 0.030 |
Why?
|
| Heterozygote | 1 | 2015 | 390 | 0.030 |
Why?
|
| Probability | 1 | 2015 | 355 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2015 | 402 | 0.030 |
Why?
|
| Sequence Deletion | 1 | 2014 | 207 | 0.030 |
Why?
|
| Inheritance Patterns | 1 | 2013 | 55 | 0.020 |
Why?
|
| DNA Copy Number Variations | 1 | 2014 | 201 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 7 | 1 | 2013 | 21 | 0.020 |
Why?
|
| CCAAT-Enhancer-Binding Proteins | 1 | 2013 | 38 | 0.020 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2014 | 188 | 0.020 |
Why?
|
| Forced Expiratory Volume | 1 | 2013 | 138 | 0.020 |
Why?
|
| Research Design | 1 | 1997 | 658 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2013 | 81 | 0.020 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 2013 | 64 | 0.020 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2012 | 29 | 0.020 |
Why?
|
| Meta-Analysis as Topic | 1 | 2012 | 86 | 0.020 |
Why?
|
| Bias | 1 | 2013 | 139 | 0.020 |
Why?
|
| Africa | 1 | 2012 | 111 | 0.020 |
Why?
|
| Aged, 80 and over | 2 | 2014 | 7371 | 0.020 |
Why?
|
| Canada | 1 | 2012 | 211 | 0.020 |
Why?
|
| Databases, Genetic | 1 | 2013 | 288 | 0.020 |
Why?
|
| Markov Chains | 1 | 2012 | 146 | 0.020 |
Why?
|
| Dendritic Cells | 1 | 2016 | 551 | 0.020 |
Why?
|
| 8,11,14-Eicosatrienoic Acid | 1 | 2011 | 11 | 0.020 |
Why?
|
| Arachidonic Acid | 1 | 2011 | 63 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2011 | 106 | 0.020 |
Why?
|
| Family | 1 | 2013 | 327 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2014 | 502 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2012 | 548 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 4020 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2016 | 2206 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2014 | 567 | 0.020 |
Why?
|
| Coronary Artery Disease | 1 | 2015 | 386 | 0.020 |
Why?
|
| Recurrence | 1 | 2013 | 1251 | 0.020 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2014 | 384 | 0.020 |
Why?
|
| Prognosis | 1 | 2018 | 4105 | 0.020 |
Why?
|
| Quantitative Trait Loci | 1 | 2014 | 662 | 0.020 |
Why?
|
| Hypersensitivity | 1 | 2011 | 166 | 0.020 |
Why?
|
| Chromosome Segregation | 1 | 2009 | 35 | 0.020 |
Why?
|
| Treatment Outcome | 3 | 2012 | 9689 | 0.020 |
Why?
|
| Pedigree | 1 | 2011 | 980 | 0.020 |
Why?
|
| Kidney Neoplasms | 1 | 2014 | 556 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2016 | 1324 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2011 | 700 | 0.020 |
Why?
|
| Health Status Disparities | 1 | 2012 | 233 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2016 | 2570 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2016 | 3591 | 0.020 |
Why?
|
| Quantitative Trait, Heritable | 1 | 2009 | 135 | 0.020 |
Why?
|
| Incidence | 1 | 2012 | 1774 | 0.020 |
Why?
|
| Cooperative Behavior | 1 | 2007 | 199 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2013 | 2582 | 0.010 |
Why?
|
| MicroRNAs | 1 | 2009 | 603 | 0.010 |
Why?
|
| DNA, Mitochondrial | 1 | 2003 | 211 | 0.010 |
Why?
|
| Genes, Insect | 1 | 2003 | 186 | 0.010 |
Why?
|
| Costs and Cost Analysis | 1 | 1999 | 155 | 0.010 |
Why?
|
| Patient Acceptance of Health Care | 1 | 1999 | 314 | 0.010 |
Why?
|
| Patient Satisfaction | 1 | 1999 | 511 | 0.010 |
Why?
|